A drug used to treat advanced melanoma that has a mutated (changed) form of a cell protein called BRAF. It is also being studied in the treatment of other types of cancer. Zelboraf blocks this mutated protein, which may stop the growth of cancer cells. It is a type of kinase inhibitor and a type of targeted therapy agent. Also called BRAF (V600E) kinase inhibitor RO5185426, PLX4032, RG7204, and vemurafenib.